We claim,

1. A purification method for producing partially purified extracellular metabolite preparation from the probiotic bacterial strain *Bacillus coagulans* SBC37-01 (Deposited in the Microbial Type Culture Collection and Gene Bank and was assigned the strain number MTCC 5856) exhibiting 99% genetic homology with the known bacterial strains *Bacillus coagulans* ATCC 31284, *Bacillus coagulans* NBRC 3887 and *Bacillus coagulans* ATCC 7050, said purification method comprising the steps of:

    (a) inoculating a culture of *Bacillus coagulans* MTCC 5856 exhibiting 99% genetic homology with the known bacterial strains *Bacillus coagulans* ATCC 31284, *Bacillus coagulans* NBRC 3887 and *Bacillus coagulans* ATCC 7050 into 1.0 liter of Glucose Yeast Extract Acetate broth medium or MRS broth containing 0.5% tween 80 or Corn steep powder media;

    (b) allowing the fermentation in the inoculated medium of step (a) to proceed for 24-48 h at 37°C with 120 rpm;

    (c) centrifuging the fermentation broth of step (b) at 4000-7000 rpm;

    (d) concentrating supernatants 10 fold by using rotary evaporator at 50°C of step (c);

    (e) adding 150 ml of chilled acetone drop by drop to 100 ml of tenfold concentrated supernatants of step (d), followed by mixing;

    (f) incubating the mixture of step (e) at 0°C for 30 minutes followed by centrifuging at 7000-8000 rpm;

    (g) discarding the pellet obtained in step (f) and collecting 60% acetone saturated supernatant (~200ml);

(h) concentrating the acetone saturated supernatant in step (g) to 50 ml by rotary evaporator;

(i) adjusting the pH to 5.0 by using 4N HCl, filtered (0.22 micron; Millex, Millipore, India) and stored at -20°C till further use; and

(j) freeze drying/spray drying/tray drying the supernatant of step (h).

2. Use of a partially purified extracellular metabolite preparation from probiotic bacterial strain *Bacillus coagulans* SBC37-01 (Deposited in the Microbial Type Culture Collection and Gene Bank and was assigned the strain number MTCC 5856) exhibiting 99% genetic homology with the known bacterial strains *Bacillus coagulans* ATCC 31284, *Bacillus coagulans* NBRC 3887 and *Bacillus coagulans* ATCC 7050 for the preparation of a medicament for microbial control of a target microbial cell.

3. The use of claim 2 wherein the microbial cell is one selected from the group comprising *Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mutans, Propionibacterium acnes, Bacillus cereus and Salmonella abony.*

4. Use of a preparation consisting essentially of partially purified extracellular metabolite preparation from probiotic bacterial strain *Bacillus coagulans* SBC37-01 (Deposited in the Microbial Type Culture Collection and Gene Bank and was assigned the strain number MTCC 5856) exhibiting 99% genetic homology with the known bacterial strains *Bacillus coagulans* ATCC 31284, *Bacillus coagulans* NBRC 3887 and *Bacillus coagulans* ATCC 7050 and a synergistic preservative blend comprising from about 61% w/w of thymol, about 38% of monolaurin and about 1% w/w of magnolol obtained from supercritical fluid extracts of *Magnolia officinalis* for the preparation of a medicament for microbial control of a microbial cell.

5. The use of claim 4 wherein the microbial cell is one selected from the group comprising *Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mutans, Propionibacterium acnes, Bacillus cereus and Salmonella abony.*

6. Use of a preparation consisting essentially of partially purified extracellular metabolite preparation from probiotic bacterial strain *Bacillus coagulans* SBC37-01 (Deposited in the Microbial Type Culture Collection and Gene Bank and was assigned the strain number MTCC 5856) exhibiting 99% genetic homology with the known bacterial strains *Bacillus coagulans* ATCC 31284, *Bacillus coagulans* NBRC 3887 and *Bacillus coagulans* ATCC 7050 alone or said preparation combined with a synergistic preservative blend comprising from about 61% w/w of thymol, about 38% of monolaurin and about 1% w/w of magnolol obtained from supercritical fluid extracts of *Magnolia officinalis* for the preparation of a medicament for inhibiting microbial biofilm formation in a biofilm producing microbial cell.

7 The use of claim 6 wherein the biofilm producing microbial cell is one selected from the group comprising *Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mutans.*

8. Use of a preparation consisting essentially of partially purified extracellular metabolite preparation from probiotic bacterial strain *Bacillus coagulans* SBC37-01 (Deposited in the Microbial Type Culture Collection and Gene Bank and was assigned the strain number MTCC 5856) exhibiting 99% genetic homology with the known bacterial strains *Bacillus coagulans* ATCC 31284, *Bacillus coagulans* NBRC 3887 and *Bacillus coagulans* ATCC 7050 alone or said preparation combined with a synergistic preservative blend comprising from about 61% w/w of thymol, about 38% of monolaurin and about 1% w/w of magnolol obtained from supercritical fluid extracts of *Magnolia officinalis* for the manufacture of a

medicament for preventing pH drop and further accumulation of biofilm of *Streptococcus mutans* in presence of sucrose in biofilm/plaque producing *Streptococcus mutans*.

9. A process of microbial control, said process comprising the step of bringing into contact *in vitro* effective concentrations of a partially purified extracellular metabolite preparation from probiotic bacterial strain *Bacillus coagulans* SBC37-01 (Deposited in the Microbial Type Culture Collection and Gene Bank and was assigned the strain number MTCC 5856) exhibiting 99% genetic homology with the known bacterial strains *Bacillus coagulans* ATCC 31284, *Bacillus coagulans* NBRC 3887 and *Bacillus coagulans* ATCC 7050 and a target microbial cell.

10. The process of claim 9 wherein the microbial cell is one selected from the group comprising *Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mutans, Propionibacterium acnes, Bacillus cereus and Salmonella abony*.

11. A process of microbial control, said process comprising the step of bringing into contact *in vitro* a microbial cell with effective concentrations of a preparation consisting essentially of partially purified extracellular metabolite preparation from probiotic bacterial strain *Bacillus coagulans* SBC37-01 (Deposited in the Microbial Type Culture Collection and Gene Bank and was assigned the strain number MTCC 5856) exhibiting 99% genetic homology with the known bacterial strains *Bacillus coagulans* ATCC 31284, *Bacillus coagulans* NBRC 3887 and *Bacillus coagulans* ATCC 7050 and a synergistic preservative blend comprising from about 61% w/w of thymol, about 38% of monolaurin and about 1% w/w of magnolol obtained from supercritical fluid extracts of *Magnolia officinalis*.

12. The process of claim 11 wherein the microbial cell is one selected from the group comprising *Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mutans, Propionibacterium acnes, Bacillus cereus and Salmonella abony.*

13. A process of inhibiting microbial biofilm formation, said process comprising step of bringing into contact *in vitro* biofilm producing microbial cells and a preparation consisting essentially of partially purified extracellular metabolite preparation from probiotic bacterial strain *Bacillus coagulans* SBC37-01 (Deposited in the Microbial Type Culture Collection and Gene Bank and was assigned the strain number MTCC 5856) exhibiting 99% genetic homology with the known bacterial strains *Bacillus coagulans* ATCC 31284, *Bacillus coagulans* NBRC 3887 and *Bacillus coagulans* ATCC 7050 alone or said preparation combined with a synergistic preservative blend comprising from about 61% w/w of thymol, about 38% of monolaurin and about 1% w/w of magnolol obtained from supercritical fluid extracts of *Magnolia officinalis.*

14. The process of claim 13 wherein the biofilm producing microbial cell is one selected from the group comprising *Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mutans.*

15. A process of preventing pH drop and further accumulation of biofilm of *Streptococcus mutans* in presence of sucrose, said process comprising step of bringing into contact *in vitro* biofilm/plaque producing *Streptococcus mutans* and a preparation consisting essentially of partially purified extracellular metabolite preparation from probiotic bacterial strain *Bacillus coagulans* SBC37-01 (Deposited in the Microbial Type Culture Collection and Gene Bank and was assigned the strain number MTCC 5856) exhibiting 99% genetic homology with the known bacterial strains *Bacillus coagulans* ATCC 31284, *Bacillus coagulans* NBRC 3887

and *Bacillus coagulans* ATCC 7050 alone or said preparation combined with a synergistic preservative blend comprising from about 61% w/w of thymol, about 38% of monolaurin and about 1% w/w of magnolol obtained from supercritical fluid extracts of *Magnolia officinalis.*